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Abstract
Sepsis is an important clinical problem with a mortality rate of 20%
to 30%. Lymphocyte apoptosis has been recognized as an
important step in the pathogenesis of experimental sepsis, by
inducing a state of ‘immune paralysis’ that renders the host
vulnerable to invading pathogens. The importance of lymphocyte
apoptosis in human disease is now confirmed by Weber and
colleagues, who demonstrate extensive apoptosis in circulating
lymphocytes from patients with severe sepsis. Weber and
colleagues’ data set the basis for further studies aimed at
modulating lymphocyte apoptosis in sepsis.
Lymphocyte apoptosis has been increasingly recognized as
an important step in the pathogenesis of sepsis, by inducing
a state of ‘immune paralysis’ that renders the host vulnerable
to invading pathogens [1]. Sepsis is an important clinical
problem, affecting more than 700,000 people each year in
the United States alone, of whom 20% to 30% die [2]. The
costs associated with sepsis amount to approximately $17
billion per year [3]. Clearly, sepsis is a major health problem
and novel therapeutic strategies are required.
The traditional paradigm has been that sepsis results from an
uncontrolled inflammatory response. This paradigm led to the
development of agents aimed at blocking key mediators of
inflammation, such as bacterial lipopolysaccharide, inter-
leukin-1, and/or tumor necrosis factor-α among others. How-
ever, when many of these agents were tested in large phase
III randomized controlled trials they failed to demonstrate a
beneficial effect [4-6]. Thus, therapeutic strategies aimed at
suppressing inflammation in sepsis have been disappointing.
Over the past decade, studies in experimental models and in
patients suggested that the immune response of sepsis
follows a biphasic pattern, with an initial ‘hyperinflammatatory’
phase characterized by high levels of pro-inflammatory
cytokines, and a second phase characterized by decreased
responsiveness of immune cells to inflammatory stimuli - the
‘immunoparalysis’ phase [7,8]. The immunoparalysis phase is
an extremely vulnerable period when patients are at particular
risk from invading bacteria. The mechanism for this immune
paralysis appears to involve apoptosis of immune cells, in
particular lymphocytes.
In a seminal study, Wang et al. [9] found that the intra-
peritoneal injection of Gram-negative bacteria to mice was
followed by apoptosis of CD4+CD8+ lymphocytes in the
thymus. Hotchkiss et al. [10,11] used a murine model of
cecal ligation and puncture to show that lymphocyte
apoptosis also involves lymphocytes from the spleen and
most other vital organ systems, and later demonstrated that
extensive lymphocyte apoptosis is also present in humans
with sepsis. Studies using loss-of-function approaches
suggested that the mechanisms of lymphocyte apoptosis in
sepsis involve both the receptor-mediated and the mito-
chondrial pathways of apoptosis, with the later playing the
predominant role (reviewed in [12]). Weber et al. [1] now
extend these laboratory observations to the bedside, by
demonstrating accelerated apoptosis in circulating lympho-
cytes (CD4, CD8 and CD19) from patients with severe
sepsis, but not in non-septic, critically ill patients. This study is
important because it confirms a pattern of activation of Bcl-2
family members predicted by animal studies, and sets the
basis for further studies aimed at modulating lymphocyte
apoptosis in sepsis.
One particularly interesting finding in Weber and colleagues’
study is that the pro-apoptotic molecule Bim was markedly
upregulated in the lymphocytes of patients with severe
sepsis. This is important because, of the different compo-
nents of the apoptosis cascade that have been tested in
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animal models (FADD, Bid, Bcl2, caspases), only deletion of
Bim is associated with complete protection from apoptosis
[13]. However, it is important to note that blockade of
lymphocyte apoptosis is not always protective in sepsis. For
example, septic mice lacking MyD88 have decreased
lymphocyte apoptosis but a significant increase in mortality
[14]. MyD88 is an important proximal component of the main
pathogen recognition pathways, suggesting that inhibition of
lymphocyte apoptosis is protective only when the ability of
the host to identify and respond to pathogens is preserved.
The study has some caveats. Patients were enrolled 4 hours
after presentation, which may have been too early in the
hospital course to catch the period of maximal apoptosis.
Also, information on the effects of severe sepsis on the
receptor-mediated pathway of apoptosis, particularly FADD
and caspase 8, would have been interesting.
In summary, the study by Weber and colleagues reaffirms and
advances our knowledge of specific pathways involved in
lymphocyte apoptosis in patients suffering from severe
sepsis, raising hopes for potential therapeutic targets that
improve mortality in this patient population.
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